Godavari Biorefineries Ltd has announced a scheduled analyst and institutional investor meeting for April 9, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The company communicated this information to both the National Stock Exchange of India Limited and BSE Limited on March 31, 2026.

Meeting Details

The company has provided specific details about the upcoming investor interaction:

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI LODR Regulations, demonstrating the company's commitment to maintaining transparency with stakeholders. Manoj Jain, Company Secretary & Compliance Officer (Membership No. F-7998), signed the official communication on March 31, 2026.

Important Disclaimers

Godavari Biorefineries Ltd has made several important clarifications regarding the meeting:

• The company does not intend to discuss any Unpublished Price Sensitive Information during this meeting
• The date and time are subject to change due to exigencies of the analyst, institutional investor, or company
• The meeting serves as a platform for management interaction with investors and analysts

Stock Exchange Communication

The company has formally notified both major stock exchanges where its shares are listed. The communication was sent to NSE (Script Name: GODAVARIB) and BSE (Script Code: 544279), ensuring compliance with listing requirements and maintaining transparency with the investment community.

Godavari Biorefineries Limited has received reaffirmation of its credit ratings from CARE Ratings Limited, with the rating agency maintaining its assessment of the integrated sugar and bio-based chemicals manufacturer's financial strength. The announcement, made on March 17, 2026, covers the company's comprehensive banking facilities and deposit programs.

Rating Details and Facility Coverage

CARE Ratings has reaffirmed ratings across multiple facility categories for the company:

The total facilities under review amount to ₹835.83 crore, representing a significant portion of the company's banking arrangements. The stable outlook reflects CARE Ratings' expectations that Godavari Biorefineries will generate healthy cash accruals and maintain adequate debt coverage metrics over the medium term.

Financial Performance and Operating Metrics

The rating reaffirmation comes despite challenging industry conditions that have impacted the company's profitability margins. Godavari Biorefineries reported total operating income growth of 11% year-on-year in FY25, reaching ₹1,870.25 crore compared to ₹1,686.67 crore in FY24.

However, the company's PBILDT margin contracted by approximately 238 basis points to 5.55% in FY25, primarily due to deterioration in the distillery segment's profitability. This decline resulted from restrictions on cane diversion to ethanol production, unavailability of molasses, and consistent increases in sugarcane prices against stable sugar and ethanol realizations.

Business Strengths and Diversification

The rating agency highlighted several key strengths supporting the reaffirmation. Godavari Biorefineries operates a fully integrated sugarcane processing facility with diversified revenue streams across sugar, distillery, co-generation, and bio-based chemicals segments. In FY25, sugar contributed 36% of total revenue, distillery operations 31%, and biochemicals 29%, with the balance from power generation.

The company's strategic location in Karnataka and Maharashtra provides access to high-recovery sugarcane producing regions. In FY25, Godavari Biorefineries achieved a gross recovery rate of 10.94%, compared to 10.78% in the previous year, demonstrating operational efficiency.

Capital Structure and Debt Metrics

The company's financial position showed mixed results, with some improvement in capital structure following its initial public offering in Q3FY25. The overall gearing ratio improved significantly to 0.94x as of March 31, 2025, from 2.79x in the previous year, primarily due to substantial prepayment of term loans using IPO proceeds.

Despite these improvements, the total debt to PBILDT ratio of 4.93x in FY25 remains above the rating agency's negative threshold of 3.5x, representing a key rating sensitivity that requires monitoring.

Future Outlook and Growth Initiatives

CARE Ratings expects gradual improvement in the company's metrics with anticipated recovery in profitability. The rating agency noted that reinstatement of sugar exports and diversion of cane for ethanol production in the ongoing sugar season should support performance recovery. Additionally, the company is commissioning a 200 KLPD grain-based distillery facility expected to become operational in Q1 FY27, which will provide operational flexibility and enhance margins through fungible feedstock capacity.

The growing contribution of specialty chemicals within the bio-based chemical division is providing incremental support to revenue and margins. The company's continued research and development investment in specialty chemicals and pharmaceutical applications is expected to provide diversification and margin enhancement over the medium term.

Source: None/Company/INE497S01012/4626f189-4cad-4f8b-a980-1a703d2c3b2e.pdf